BRPI1011258A2 - sais de fumarato, uso destes, composição farmacêutica que os compreende e processos para preparação da dita composição e de difumarato mono-hidratado de 2-(ciclo-hexilmetil)-n-{2-[(2s)-1-metilporrolidin-2-il]etil}-1,2,3,4-tetra-hirdoisoquinolina-7-sulfonamida - Google Patents

sais de fumarato, uso destes, composição farmacêutica que os compreende e processos para preparação da dita composição e de difumarato mono-hidratado de 2-(ciclo-hexilmetil)-n-{2-[(2s)-1-metilporrolidin-2-il]etil}-1,2,3,4-tetra-hirdoisoquinolina-7-sulfonamida

Info

Publication number: BRPI1011258A2
Authority: BR; Brazil
Prior art keywords: composition; methylporrolidin; tetrahydroisoquinoline; cyclohexylmethyl; sulfonamide
Prior art date: 2009-06-26

Application number

BRPI1011258A

Other languages

English (en)

Inventor

Beverly C Langevin

Daniel Sherer

Dinubhai H Shah

Robert Allan Farr

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-26

Filing date

2010-06-24

Publication date

2016-03-22

2010-06-24 Application filed by Sanofi Sa filed Critical Sanofi Sa

2016-03-22 Publication of BRPI1011258A2 publication Critical patent/BRPI1011258A2/pt

Links

VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 title 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
239000000203 mixture Substances 0.000 title 1
150000004682 monohydrates Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Gynecology & Obstetrics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI1011258A 2009-06-26 2010-06-24 sais de fumarato, uso destes, composição farmacêutica que os compreende e processos para preparação da dita composição e de difumarato mono-hidratado de 2-(ciclo-hexilmetil)-n-{2-[(2s)-1-metilporrolidin-2-il]etil}-1,2,3,4-tetra-hirdoisoquinolina-7-sulfonamida BRPI1011258A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US22068309P	2009-06-26	2009-06-26
FR0959110		2009-12-17
PCT/US2010/039731 WO2010151611A1 (en)	2009-06-26	2010-06-24	Novel fumarate salts of a histamine h3 receptor antagonist

Publications (1)

Publication Number	Publication Date
BRPI1011258A2 true BRPI1011258A2 (pt)	2016-03-22

Family

ID=43386878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1011258A BRPI1011258A2 (pt)	2009-06-26	2010-06-24	sais de fumarato, uso destes, composição farmacêutica que os compreende e processos para preparação da dita composição e de difumarato mono-hidratado de 2-(ciclo-hexilmetil)-n-{2-[(2s)-1-metilporrolidin-2-il]etil}-1,2,3,4-tetra-hirdoisoquinolina-7-sulfonamida

Country Status (25)

Country	Link
US (1)	US8664245B2 (pt)
EP (1)	EP2445899B1 (pt)
JP (1)	JP6053519B2 (pt)
KR (1)	KR101804749B1 (pt)
CN (1)	CN102803247B (pt)
AR (1)	AR077223A1 (pt)
AU (1)	AU2010264422B2 (pt)
BR (1)	BRPI1011258A2 (pt)
CA (1)	CA2766154C (pt)
CO (1)	CO6480943A2 (pt)
DO (1)	DOP2011000398A (pt)
ES (1)	ES2587064T3 (pt)
IL (1)	IL216924A0 (pt)
MA (1)	MA33378B1 (pt)
MX (1)	MX2011012824A (pt)
NZ (1)	NZ597219A (pt)
PE (1)	PE20121403A1 (pt)
PL (1)	PL2445899T3 (pt)
RU (1)	RU2537847C2 (pt)
SG (1)	SG176645A1 (pt)
TN (1)	TN2011000620A1 (pt)
TW (1)	TWI462915B (pt)
UY (1)	UY32738A (pt)
WO (1)	WO2010151611A1 (pt)
ZA (1)	ZA201108838B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR080375A1 (es)	2010-03-05	2012-04-04	Sanofi Aventis	Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
WO2013151982A1 (en)	2012-04-03	2013-10-10	Arena Pharmaceuticals, Inc.	Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) *	2012-04-06	2013-10-09	Sanofi	Use of an h3 receptor antagonist for the treatment of alzheimer's disease
JP2015524400A (ja) *	2012-07-19	2015-08-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製
EP3043799A1 (en) *	2013-09-09	2016-07-20	Sanofi	An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4228170A (en)	1979-08-30	1980-10-14	Smithkline Corporation	7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds
EP0306375A1 (fr)	1987-08-07	1989-03-08	Synthelabo	Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique
IL89156A (en)	1988-07-12	1993-05-13	Synthelabo	Derivatives of 2-((4-piperidinyl) methyl)- 1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics
EP1200410A1 (en)	1999-07-29	2002-05-02	Egis Gyogyszergyar Rt.	Isoquinoline derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance
US6825198B2 (en) *	2001-06-21	2004-11-30	Pfizer Inc	5-HT receptor ligands and uses thereof
WO2003055848A2 (en)	2001-12-26	2003-07-10	Bayer Healthcare Ag	Urea derivatives as vr1- antagonists
US7790231B2 (en)	2003-07-10	2010-09-07	Brewer Science Inc.	Automated process and apparatus for planarization of topographical surfaces
FR2870846B1 (fr) *	2004-05-25	2006-08-04	Sanofi Synthelabo	Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
CA2602336A1 (en) *	2005-03-31	2006-10-05	Ucb Pharma S.A.	Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
WO2007108936A2 (en) *	2006-03-15	2007-09-27	Wyeth	N-substituted-azacyclylamines as histamine-3 antagonists
PE20081152A1 (es) *	2006-10-06	2008-08-10	Wyeth Corp	Azaciclilaminas n-sustituidas como antagonistas de histamina-3
WO2008144305A1 (en) *	2007-05-18	2008-11-27	Janssen Pharmaceutica N.V.	Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
CA2693138A1 (en) *	2007-07-16	2009-01-22	Wyeth Llc	Aminoalkylazole derivatives as histamine-3 antagonists

2010
- 2010-06-24 NZ NZ597219A patent/NZ597219A/xx not_active IP Right Cessation
- 2010-06-24 PE PE2011002152A patent/PE20121403A1/es not_active Application Discontinuation
- 2010-06-24 MA MA34475A patent/MA33378B1/fr unknown
- 2010-06-24 PL PL10729017T patent/PL2445899T3/pl unknown
- 2010-06-24 KR KR1020117030933A patent/KR101804749B1/ko not_active Expired - Fee Related
- 2010-06-24 AU AU2010264422A patent/AU2010264422B2/en not_active Ceased
- 2010-06-24 CN CN201080028665.3A patent/CN102803247B/zh not_active Expired - Fee Related
- 2010-06-24 SG SG2011089422A patent/SG176645A1/en unknown
- 2010-06-24 WO PCT/US2010/039731 patent/WO2010151611A1/en not_active Ceased
- 2010-06-24 EP EP10729017.3A patent/EP2445899B1/en active Active
- 2010-06-24 JP JP2012517706A patent/JP6053519B2/ja not_active Expired - Fee Related
- 2010-06-24 ES ES10729017.3T patent/ES2587064T3/es active Active
- 2010-06-24 CA CA2766154A patent/CA2766154C/en not_active Expired - Fee Related
- 2010-06-24 AR ARP100102239A patent/AR077223A1/es unknown
- 2010-06-24 RU RU2012102671/04A patent/RU2537847C2/ru not_active IP Right Cessation
- 2010-06-24 MX MX2011012824A patent/MX2011012824A/es not_active Application Discontinuation
- 2010-06-24 BR BRPI1011258A patent/BRPI1011258A2/pt not_active IP Right Cessation
- 2010-06-25 TW TW099120734A patent/TWI462915B/zh not_active IP Right Cessation
- 2010-06-25 UY UY0001032738A patent/UY32738A/es not_active Application Discontinuation
2011
- 2011-12-01 ZA ZA2011/08838A patent/ZA201108838B/en unknown
- 2011-12-05 TN TNP2011000620A patent/TN2011000620A1/en unknown
- 2011-12-08 US US13/314,772 patent/US8664245B2/en not_active Expired - Fee Related
- 2011-12-12 IL IL216924A patent/IL216924A0/en unknown
- 2011-12-21 DO DO2011000398A patent/DOP2011000398A/es unknown
- 2011-12-23 CO CO11177476A patent/CO6480943A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP6053519B2 (ja)	2016-12-27
TN2011000620A1 (en)	2013-05-24
CA2766154A1 (en)	2010-12-29
US20120149728A1 (en)	2012-06-14
WO2010151611A1 (en)	2010-12-29
KR20120039555A (ko)	2012-04-25
US8664245B2 (en)	2014-03-04
CN102803247A (zh)	2012-11-28
JP2012531424A (ja)	2012-12-10
AU2010264422A1 (en)	2012-02-02
NZ597219A (en)	2013-05-31
AU2010264422B2 (en)	2014-12-18
AR077223A1 (es)	2011-08-10
RU2012102671A (ru)	2013-08-10
SG176645A1 (en)	2012-01-30
DOP2011000398A (es)	2012-01-31
CN102803247B (zh)	2014-11-05
CA2766154C (en)	2015-04-07
TWI462915B (zh)	2014-12-01
PL2445899T3 (pl)	2017-08-31
EP2445899B1 (en)	2016-05-11
KR101804749B1 (ko)	2017-12-05
MX2011012824A (es)	2012-01-27
UY32738A (es)	2011-01-31
MA33378B1 (fr)	2012-06-01
ES2587064T3 (es)	2016-10-20
TW201103911A (en)	2011-02-01
EP2445899A1 (en)	2012-05-02
RU2537847C2 (ru)	2015-01-10
IL216924A0 (en)	2012-03-01
PE20121403A1 (es)	2012-11-02
CO6480943A2 (es)	2012-07-16
ZA201108838B (en)	2012-08-29

Similar Documents

Publication	Publication Date	Title
BRPI1006162A2 (pt)	2019-09-24	"composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
CL2007003187A1 (es)	2008-03-07	Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
BRPI0906475A2 (pt)	2015-07-14	Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto
BRPI0819957A2 (pt)	2015-09-15	"composição farmacêutica estável e sustentada de hidrocloreto de bupropiona e processo para a preparação da mesma"
BRPI0817423A2 (pt)	2015-06-16	Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto
BRPI0906064A2 (pt)	2015-06-30	"peptídeo, processo para obtenção de um peptídeo de fórmula geral (i), composição cosmética ou farmacêutica e uso de um peptídeo de fórmula geral (i)"
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
SI2178881T1 (sl)	2014-01-31	Novi derivati 6-triazolopiridazin-sulfanil benzotiazola in benzimidazola, postopek za njihovo pripravo, njihova uporaba kot zdravila, farmacevtski sestavki in nova uporaba, zlasti kot Met inhibitorji
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
UY32203A (es)	2010-05-31	Amino pirimidinas y su uso en terapia
CL2014000732A1 (es)	2014-09-26	Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende.
CL2012000026A1 (es)	2012-10-05	Formulación farmacéutica acuosa que contiene una insulina, un análogo de insulina o un derivado insulínico, o una de sus sales farmacológicamente tolerables, y metionina; proceso para preparar dicha formulación; medicamento que la contiene; y su uso para tratar la diabetes mellitus.
BRPI0818459A2 (pt)	2015-04-14	Composição farmacêutica adequada para uso oftálmico.
BRPI0816320A2 (pt)	2015-03-24	Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
CL2007003472A1 (es)	2008-08-22	Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
BR112014009084A2 (pt)	2017-05-09	polimorfos de arry-380, inibidor seletivo de herb2 e composições farmacêuticas que contenham os mesmos
BRPI1008727A2 (pt)	2016-03-08	derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos
BRPI0607423A2 (pt)	2016-11-08	forma microcristalina de um composto, processo para a preparação da mesma, uso de uma forma microcristalina, composição farmacêutica e processo para a preparação da mesma, e, produto
AR065278A1 (es)	2009-05-27	Sales de derivado de benzotiazol
BRPI0908738A2 (pt)	2017-06-13	composto, medicamento, uso de um composto, e, processo para preparar os compostos
BRPI0914912A2 (pt)	2017-06-20	processo para a preparação de um composto, e de um inibidor de mtor quinase, sal de fumarato, composição farmacêutica, uso de um sal de fumarato, e, métodos para produzir um efeito inibitório mtor, e para produzir um efeito anti-câncer em um animal de sangue quente
BR112012004173A2 (pt)	2017-05-30	"composto, composição, método para preparar uma composição, e, uso de um composto"
BRPI0916072A2 (pt)	2015-11-10	"uso de uma formulação, formulação farmacêutica, usos de um anticorpo 2h7 humanizado, método, método para aumentar a biodisponibilidade de um anticorpo e método de diálise in vitro"
BR112013002651A2 (pt)	2016-05-31	forma sólida do sal de cloridrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina, processo para o preparo da mesma, uso mesma e composição farmacêutica compreendendo a mesma
CL2008000573A1 (es)	2008-05-16	Forma cristalina de la sal 3-endo-(8-[2-[ciclohexilmetil-((s)-2,3-dihidroxi-propionil) amino]etil]-8aza-biciclo[3,2,1] oct-3-il)benzamida; proceso para la preparacion de dicha sal; composicion farmaceutica que comprende a dicha sal; y su uso en disfu

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-04-16	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2019-04-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-06	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.